<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MAY 31, 1999
COMMISSION FILE NUMBER 0-5905
CHATTEM, INC.
A TENNESSEE CORPORATION
I.R.S. EMPLOYER IDENTIFICATION NO. 62-0156300
1715 WEST 38TH STREET
CHATTANOOGA, TENNESSEE 37409
TELEPHONE: 423-821-4571
REGISTRANT HAS FILED ALL REPORTS REQUIRED TO BE FILED BY SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934 DURING THE PRECEDING 12 MONTHS, AND HAS BEEN
SUBJECT TO SUCH FILING REQUIREMENTS FOR THE PAST 90 DAYS.
AS OF JULY 12, 1999, 9,793,733 SHARES OF THE COMPANY'S COMMON STOCK, WITHOUT PAR
VALUE, WERE OUTSTANDING.
<PAGE>
CHATTEM, INC.
INDEX
<TABLE>
<CAPTION>
PAGE NO.
--------
<S> <C>
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Balance Sheets as of May 31, 1999 and
November 30, 1998........................................................... 3
Consolidated Statements of Income for the Three and Six
Months Ended May 31, 1999 and 1998.......................................... 5
Consolidated Statements of Cash Flows for the Six Months Ended
May 31, 1999 and 1998....................................................... 6
Notes to Consolidated Financial Statements.................................... 7
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations..................................................... 11
PART II. OTHER INFORMATION
Item 1. Legal Proceedings...................................................... 22
Item 4. Submission of Matters to a Vote of Security Holders.................... 22
Item 6. Exhibits and Reports on Form 8-K....................................... 22
SIGNATURES........................................................................ 23
EXHIBIT 11 - Statement Regarding Computation of Per Share Earnings
EXHIBIT 27 - Financial Data Schedule
</TABLE>
2
<PAGE>
PART 1. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
CHATTEM, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands)
<TABLE>
<CAPTION>
MAY 31, NOVEMBER 30,
ASSETS 1999 1998
- ------ ---------------- ----------------
(Unaudited)
<S> <C> <C>
CURRENT ASSETS:
Cash and cash equivalents............................... $ 4,869 $ 2,076
Accounts receivable, less allowance for doubtful 58,400 36,581
accounts of $850 at May 31, 1999 and $775 at
November 30, 1998.....................................
Refundable and deferred income taxes.................... 3,058 3,049
Inventories............................................. 22,980 19,606
Prepaid expenses and other current assets............... 1,149 784
--------------- ----------------
Total current assets.................................. 90,456 62,096
--------------- ----------------
PROPERTY, PLANT AND EQUIPMENT, NET ....................... 20,256 18,146
--------------- ----------------
OTHER NONCURRENT ASSETS:
Investment in Elcat, Inc. .............................. 3,242 3,102
Patents, trademarks and other purchased product rights, net 360,200 272,226
Debt issuance costs, net................................ 12,461 10,091
Other................................................... 3,161 3,351
--------------- ----------------
Total other noncurrent assets......................... 379,064 288,770
--------------- ----------------
TOTAL ASSETS........................................ $ 489,776 $ 369,012
--------------- ----------------
--------------- ----------------
The accompanying notes are an integral part of these consolidated financial statements.
</TABLE>
3
<PAGE>
CHATTEM, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands)
<TABLE>
<CAPTION>
MAY 31, NOVEMBER 30,
LIABILITIES AND SHAREHOLDERS' EQUITY 1999 1998
- ------------------------------------ ------------ ------------
(Unaudited)
<S> <C> <C>
CURRENT LIABILITIES:
Current maturities of long-term debt.................................. $ 9,000 $ 17,444
Accounts payable...................................................... 13,244 12,733
Payable to bank....................................................... 128 1,026
Accrued liabilities................................................... 42,246 30,209
------------ ------------
Total current liabilities........................................... 64,618 61,412
------------ ------------
LONG-TERM DEBT, less current maturities ................................ 378,547 273,913
------------ ------------
DEFERRED INCOME TAXES .................................................. 6,826 6,826
------------ ------------
OTHER NONCURRENT LIABILITIES ........................................... 2,150 2,110
------------ ------------
SHAREHOLDERS' EQUITY:
Preferred shares, without par value, authorized 1,000,
none issued......................................................... -- --
Common shares, without par value, authorized 50,000,
issued 9,764 at May 31, 1999 and 9,574 at
November 30, 1998................................................... 2,034 1,994
Paid-in surplus....................................................... 73,818 69,068
Accumulated deficit................................................... (36,743) (44,960)
------------ ------------
39,109 26,102
Cumulative other comprehensive income -
Foreign currency translation adjustment ............................ (1,474) (1,351)
------------ ------------
Total shareholders' equity......................................... 37,635 24,751
------------ ------------
TOTAL LIABILITIES AND SHAREHOLDERS'
EQUITY........................................................ $ 489,776 $ 369,012
------------ ------------
------------ ------------
The accompanying notes are an integral part of these consolidated financial statements.
</TABLE>
4
<PAGE>
CHATTEM, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited and in thousands, except per share amounts)
<TABLE>
<CAPTION>
FOR THE THREE MONTHS FOR THE SIX MONTHS
ENDED MAY 31, ENDED MAY 31,
-------------------------- ---------------------------
1999 1998 1999 1998
------------ ------------ ------------ ------------
<S> <C> <C> <C> <C>
NET SALES........................................ $ 83,441 $ 58,545 $ 146,169 $ 93,466
----------- ----------- ----------- ----------
COSTS AND EXPENSES:
Cost of sales.................................. 21,794 15,854 38,674 25,536
Advertising and promotion...................... 33,315 23,202 58,053 38,382
Selling, general and administrative............ 7,984 6,741 14,684 11,900
----------- ----------- ----------- ----------
Total costs and expenses..................... 63,093 45,797 111,411 75,818
----------- ----------- ---------- ----------
INCOME FROM OPERATIONS ......................... 20,348 12,748 34,758 17,648
----------- ----------- ----------- ----------
OTHER INCOME (EXPENSE):
Interest expense............................... (9,342) (7,332) (18,148) (11,512)
Investment and other income.................... 113 243 244 435
Gain on product divestiture.................... -- 10,442 -- 10,442
----------- ----------- ----------- -----------
Total other income (expense)................. (9,229) 3,353 (17,904) (635)
----------- ----------- ----------- -----------
INCOME BEFORE INCOME TAXES AND
EXTRAORDINARY LOSS............................... 11,119 16,101 16,854 17,013
PROVISION FOR INCOME TAXES ...................... 4,179 6,032 6,337 6,335
----------- ----------- ----------- ----------
INCOME BEFORE EXTRAORDINARY LOSS ................ 6,940 10,069 10,517 10,678
EXTRAORDINARY LOSS ON EARLY
EXTINGUISHMENT OF DEBT, NET ................... (1,873) (1,901) (2,300) (1,901)
----------- ----------- ----------- -----------
NET INCOME....................................... $ 5,067 $ 8,168 $ 8,217 $ 8,777
----------- ----------- ----------- ----------
----------- ----------- ----------- ----------
COMMON SHARES:
Weighted average number outstanding (basic).... 9,741 9,370 9,726 9,149
----------- ----------- ----------- ----------
----------- ----------- ----------- ----------
Weighted average and dilutive potential number
outstanding.................................. 10,112 9,829 10,105 9,548
----------- ----------- ----------- ----------
----------- ----------- ----------- ----------
NET INCOME (LOSS) PER COMMON SHARE:
Basic:
Income before extraordinary loss............. $ .71 $ 1.07 $ 1.08 $ 1.17
Extraordinary loss........................... (.19) (.20) (.24) (.21)
----------- ----------- ----------- ----------
Total basic................................ $ .52 $ .87 $ .84 $ .96
----------- ----------- ----------- ----------
----------- ----------- ----------- ----------
Diluted:
Income before extraordinary loss............. $ .69 $ 1.02 $ 1.04 $ 1.12
Extraordinary loss........................... (.19) (.19) (.23) (.20)
----------- ----------- ----------- ----------
Total diluted.............................. $ .50 $ .83 $ .81 $ .92
----------- ----------- ----------- ----------
----------- ----------- ----------- ----------
The accompanying notes are an integral part of these consolidated financial statements.
</TABLE>
5
<PAGE>
CHATTEM, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited and in thousands)
<TABLE>
<CAPTION>
FOR THE SIX MONTHS ENDED MAY 31,
1999 1998
------------ -----------
<S> <C> <C>
OPERATING ACTIVITIES:
Net income................................................... $ 8,217 $ 8,777
Adjustments to reconcile net income to net cash provided by
operating activities:
Depreciation and amortization............................ 7,113 4,121
Extraordinary loss on early extinguishment of debt, net.. 2,300 1,901
Gain on sale of trademarks and other product rights...... -- (10,442)
Dividend receivable from Elcat, Inc. .................... (140) (328)
Other, net............................................... 28 111
Changes in operating assets and liabilities:
Increase in accounts receivable, net of acquisitions.... (21,819) (16,434)
Decrease in inventories................................. 119 910
Increase in refundable and deferred income taxes........ (9) --
(Increase) decrease in prepaid and other current assets.. (149) 729
Increase in accounts payable and accrued liabilities.... 13,476 15,624
------------ -----------
Net cash provided by operating activities........... 9,136 4,969
------------ -----------
INVESTING ACTIVITIES:
Purchases of property, plant and equipment............... (2,473) (7,348)
Proceeds from sale of investment......................... 387 --
Purchase of trademarks and other related assets.......... (91,293) (165,128)
Proceeds from sale of trademarks and other product rights -- 11,750
Other, net............................................... (1,147) (293)
------------ -----------
Net cash used in investing activities............... (94,526) (161,019)
------------ -----------
FINANCING ACTIVITIES:
Repayment of long-term debt.............................. (126,493) (95,998)
Proceeds from long-term debt............................. 221,781 262,365
Proceeds from exercise of stock options and warrants..... 675 2,458
Repurchase of common stock............................... (885) --
Debt issuance costs...................................... (4,829) (8,297)
Cancellation of interest rate swap agreements............ (1,155) --
Decrease in payable to bank.............................. (898) (865)
------------ -----------
Net cash provided by financing activities........... 88,196 159,663
------------ -----------
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND
CASH EQUIVALENTS................................................ (13) (8)
------------ -----------
CASH AND CASH EQUIVALENTS:
Increase for the period................................... 2,793 3,605
At beginning of period.................................... 2,076 4,858
------------ -----------
At end of period.......................................... $ 4,869 $ 8,463
------------ -----------
------------ -----------
PAYMENTS FOR:
Interest.................................................. $ 17,170 $ 8,053
Taxes..................................................... $ 3,981 $ 272
The accompanying notes are an integral part of these consolidated financial statements.
</TABLE>
6
<PAGE>
CHATTEM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note: All monetary amounts are expressed in thousands of dollars unless
contrarily evident.
1. The accompanying unaudited consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for
interim financial information and the instructions to Form 10-Q and Rule
10-01 of Regulation S-X. Accordingly, they do not include all of the
information and footnotes required by generally accepted accounting
principles for complete financial statements. These consolidated financial
statements should be read in conjunction with the audited consolidated
financial statements and related notes thereto included in the Company's
Annual Report to Shareholders for the year ended November 30, 1998. The
1998 Annual Report has previously been filed with the Securities and
Exchange Commission as an exhibit to the Company's Form 10-K. The
accompanying unaudited consolidated financial statements, in the opinion of
management, include all adjustments necessary for a fair presentation. All
such adjustments are of a normal recurring nature. All significant
intercompany transactions and balances have been eliminated.
2. The Company incurs significant expenditures on television, radio and print
advertising to support its nationally branded over-the-counter health and
skin care products. Customers purchase products from the Company with the
understanding that the brands will be supported by the Company's extensive
media advertising. This advertising supports the retailers' sales effort
and maintains the important brand franchise with the consuming public.
Accordingly, the Company considers its advertising program to be clearly
implicit in its sales arrangements with its customers. Therefore, the
Company believes it is appropriate to allocate a percentage of the
necessary supporting advertising expenses to each dollar of sales by
charging a percentage of sales on an interim basis based upon anticipated
annual sales and advertising expenditures (in accordance with APB Opinion
No. 28) and adjusting that accrual to the actual expenses incurred at the
end of the year.
3. The results of operations for the periods presented are not necessarily
indicative of the results to be expected for the respective full years.
4. Inventories consisted of the following at May 31, 1999 and November 30,
1998:
<TABLE>
<CAPTION>
May 31, November 30,
1999 1998
-------- ------------
<S> <C> <C>
Raw materials and work in process $ 9,140 $ 7,903
Finished goods................... 16,250 14,113
Excess of current cost over LIFO
values......................... (2,410) (2,410)
-------- ---------
Total inventories............ $ 22,980 $ 19,606
-------- ---------
-------- ---------
</TABLE>
7
<PAGE>
5. Accrued liabilities consisted of the following at May 31, 1999 and
November 30, 1998:
<TABLE>
<CAPTION>
May 31, November 30,
1999 1998
---------- ------------
<S> <C> <C>
Income and other taxes ........ $ 4,464 $ 3,881
Salaries, wages and commissions 2,298 2,850
Advertising and promotion ..... 21,071 8,896
Interest ...................... 6,880 5,969
Product acquisitions and
divestitures ................. 3,635 3,290
Royalties ..................... 143 2,889
Other ......................... 3,755 2,434
------- -------
Total accrued liabilities ..... $42,246 $30,209
------- -------
------- -------
</TABLE>
6. Effective December 1, 1998, the Company adopted Statements of Financial
Accounting Standards (SFAS) No. 130, "Reporting Comprehensive Income";
SFAS No. 131, "Disclosure about Segments of an Enterprise and Related
Information" and SFAS No. 132, "Employers' Disclosure about Pensions and
other Retirement Benefits."
SFAS No. 130 requires the Company to include a financial statement
presentation of comprehensive income and its components. Note 7 of these
Notes to Consolidated Financial Statements presents this information. The
Shareholders' Equity sections of the accompanying Consolidated Balance
Sheets as of May 31, 1999 and November 30, 1998 also present the
"Cumulative other comprehensive income" portion of the respective
cumulative comprehensive income.
SFAS No. 131 requires the Company to expand the financial statement
disclosures for operating segments, products and services and geographic
areas. For fiscal 1999, the Company in accordance with the provisions of
this statement has elected not to provide the disclosures for interim
reporting periods, but will present the required information in its annual
report for fiscal 1999 on a comparative annual basis.
SFAS No. 132 revises the Company's disclosures about pension and other
post retirement benefits plans. These revisions will be reflected in the
Company's annual report for fiscal 1999.
7. Comprehensive income consisted of the following components for the three
and six months ended May 31, 1999 and 1998, respectively:
<TABLE>
<CAPTION>
For the Three Months For the Six Months
Ended May 31, Ended May 31,
1999 1998 1999 1998
----------- ----------- ----------- ----------
<S> <C> <C> <C> <C>
Net income..................... $ 5,067 $ 8,168 $ 8,217 $ 8,777
Other - foreign currency
translation adjustment...... (52) 102 (123) 9
------------ ------------ ------------ ------------
Total $ 5,015 $ 8,270 $ 8,094 $ 8,786
------------ ------------ ------------ ------------
------------ ------------ ------------ ------------
</TABLE>
8
<PAGE>
8. On December 21, 1998, the Company acquired the DEXATRIM, SPORTSCREME,
ASPERCREME, CAPZASIN-P, CAPZASIN-HP and ARTHRITIS HOT brands from Thompson
Medical Company, Inc. (the "Thompson Medical brands") for $95,000. The
purchase price consisted of $90,000 cash and 125,500 shares of the
Company's common stock. The cash portion of the purchase price was financed
by a new senior credit facility.
9. On December 21, 1998, the Company refinanced its existing credit facilities
with $165,000 in senior secured credit facilities (the "Credit
Facilities"). The Credit Facilities were provided by a syndicate of
commercial banks, led by Bank of America as agent. The Credit Facilities
include a $50,000 revolving credit facility and a $115,000 term loan. The
Credit Facilities were used to refinance existing senior debt, to finance
the acquisition of the Thompson Medical brands and related fees and
expenses and to finance working capital and other general corporate needs.
The $50,000 revolving credit facility matures on the earlier of (i)
December 21, 2003 and (ii) the date on which the term loan is repaid in
full. The $115,000 term loan matures on December 21, 2003. The Credit
Facilities contain covenants, representations, warranties and other
agreements by the Company that are customary in loan agreements and
securities instruments relating to financing of this type.
The company may elect either the greater of (i) the prime rate or federal
funds rate plus .5% or (ii) a floating rate or Eurodollar interest rate
option applicable to the term and revolving line loans under the Credit
Facilities. The prime rate and Eurodollar interest rate options are based
on a base rate plus a rate margin that fluctuates on the basis of the
Company's senior leverage ratio.
10. On May 7, 1999 the Company issued an additional $75,000 of its 8.875%
(priced to yield 8.8125%) senior subordinated notes under its indenture
relating to the issuance of its $200,000 of 8.875% notes on March 24, 1998.
The additional notes mature on April 1, 2008 and were issued under the
Company's $250,000 shelf registration statement filed on December 21, 1998
with the Securities and Exchange Commission. The net proceeds from the
issuance of the additional notes were used to retire $41,500 of the then
outstanding balance of the Company's $115,000 term bank loan and the
outstanding balance of $25,500 of its revolving bank loan dated December
21, 1998.
Concurrent with the closing of the $75,000 note issue, the Company amended
its senior credit facility. The amended facility, provided by a syndicate
of banks, consists of a $70,000 term loan and a $50,000 revolving credit
facility. The revolving credit facility and the term loan both mature on
December 21, 2003. The credit facility contains covenants, representations,
warranties and other agreements by the Company that are customary in loan
agreements relating to financing of this type.
11. In February 1999 a complaint was filed against the Company by Genderm
Corporation ("Genderm") in the U.S. District Court for the District of
Arizona. The complaint alleged, among other things, that the formulations
of CAPZASIN-P, CAPZASIN-HP and ICY HOT Arthritis Therapy Gel infringed U.S.
Patent 4,485,450 owned by Joel Bernstein, M.D. and licensed to Genderm (the
"Patent"). The complaint requested injunctive relief, compensatory and
treble damages, costs and attorneys fees. A hearing on the preliminary
injunction was held on April 13-14, 1999. On May 6, 1999 U.S. District
Court for the District of Arizona held that Genderm had carried its burden
of proving a substantial likelihood of success and ultimately showing that
the Patent was infringed and issued a preliminary injunction prohibiting
the Company from shipping CAPZASIN-P cream, CAPZASIN-HP cream and ICY HOT
Arthritis Therapy Gel. Following the issuance of the preliminary
injunction, Chattem reached a settlement with Genderm pursuant to which
Chattem made a single payment in exchange for the dismissal of the
complaint and a fully paid license to use the Patent until its expiration.
9
<PAGE>
12. During May 1999 the Company retired $6,750 face amount of its 12.75% Senior
Subordinated Notes, due 2004. The remaining principal amount outstanding is
$42,901.
In connection with the repayment of portions of its bank loans and its
12.75% notes, the Company recognized an extraordinary loss on early
extinguishment of debt of $2,300, net of taxes, for the six months ended
May 31, 1999. This loss primarily related to the write-off of debt
issuance costs connected with outstanding long-term debt retired before
maturity in the current period, the premium paid on the retirement of
the 12.75% notes and termination of interest rate swaps.
13. In March 1999 the Company repurchased for $885, and returned to unissued,
30,000 shares of its common stock, without par value.
14. For purposes of reporting cash flows, the Company considers all short-term
deposits and investments with original maturities of three months or less
to be cash equivalents.
10
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
Note: All monetary amounts are expressed in thousands of dollars unless
contrarily evident.
GENERAL
On December 21, 1998, the Company acquired the DEXATRIM, SPORTSCREME,
ASPERCREME, CAPZASIN-P, CAPZASIN-HP and ARTHRITIS HOT brands from Thompson
Medical Company, Inc. for $95,000. The purchase price consisted of $90,000 cash
and 125,500 shares of the Company's common stock. The cash portion of the
purchase price was financed by a new senior credit facility.
On May 7, 1999 the Company issued an additional $75,000 of its 8.875% (priced to
yield 8.8125%) senior subordinated notes under its indenture relating to the
issuance of its $200,000 of 8.875% notes on March 24, 1998. The additional notes
mature on April 1, 2008 and were issued under the Company's $250,000 shelf
registration statement filed on December 21, 1998 with the Securities and
Exchange Commission. The net proceeds from the issuance of the additional notes
were used to retire $41,500 of the then outstanding balance of the Company's
$115,000 term bank loan and the outstanding balance of $25,500 of its revolving
bank loan dated December 21, 1998.
Concurrent with the closing of the $75,000 note issue, Chattem amended its
senior credit facility. The amended facility, provided by a syndicate of banks,
consists of a $70,000 term loan and a $50,000 revolving credit facility. The
revolving credit facility and the term loan both mature on December 21, 2003.
The credit facility contains covenants, representations, warranties and other
agreements by Chattem that are customary in loan agreements relating to
financing of this type.
For the second quarter of fiscal 1999, net sales increased 42.5% to $83,441 from
$58,545 for the corresponding prior year period, while operating income rose
more rapidly than sales, growing 59.6% to $20,348 for 1999 from $12,748 in 1998.
Net income before extraordinary loss and product divestiture for the 1999 period
was $6,940, or $.69 per share, as compared to $3,595, or $.37 per share, for the
comparable 1998 period, an increase of 93.0%. The increase in earnings per share
was achieved despite the weighted average and dilutive potential number of
shares outstanding increasing 3.0% from 1998 to 1999.
For the first six months of fiscal 1999, net sales were $146,169 compared to
$93,466 for the same period of 1998, a 56.4% increase. Income from operations
for the 1999 period was $34,758 versus $17,648 in the comparable 1998 period, a
97.0% increase. Net income before extraordinary loss for the first six months of
fiscal 1999 was $10,517, or $1.04 per share, compared to $4,204, or $.44 per
share, excluding the gain on the sale of CORNSILK completed in the second fiscal
quarter of 1998, an increase of 150.2%.
The BAN brand, acquired in March 1998, the Thompson Medical brands, purchased in
December 1998, and the continuing strong performance of the GOLD BOND family of
products, including the continuing strength of GOLD BOND Medicated Body Lotion,
were primarily responsible for the revenue growth and the improvement in the
Company's operating results for the three and six months ended May 31, 1999.
During May 1999 the Company retired $6,750 face amount of its 12.75% Senior
Subordinated Notes, due 2004.
11
<PAGE>
In connection with the repayment of portions of its bank loans and its 12.75%
notes, the Company recognized an extraordinary loss on early extinguishment of
debt of $2,300, net of taxes, for the six months ended May 31, 1999. This
loss primarily related to the write-off of debt issuance costs connected with
outstanding long-term debt retired before maturity in the current period, the
premium paid on the retirement of the 12.75% notes and the termination of
interest rate swaps.
In March 1999 the Company repurchased for $885, and returned to unissued, 30,000
shares of its common stock, without par value.
The Company will continue to seek sales increases through a combination of
acquisitions and internal growth while maintaining high operating income levels.
As previously high-growth brands mature, sales increases will become even more
dependent on acquisitions and the development of successful line extensions of
existing products. During the first six months of fiscal 1999, the Company
introduced the following line extensions/new products: BAN Ultra Dry Roll-On,
BAN Ultra Dry Solid Stick, GOLD BOND Triple Antibiotic Ointment, REPOSE Stress
Relief Formula, BULLFROG MAGICBLOCK, SUN-IN Super Streaks and PHISODERM 4 Way
Daily Acne Cleanser. Also, new packaging for the entire BAN brand was introduced
in the second quarter of fiscal 1999. Strategically, the Company continually
evaluates its products as part of its growth strategy and, in instances where
the Company's objectives are not realized, will dispose of these brands and
redeploy the assets to reduce indebtedness.
12
<PAGE>
RESULTS OF OPERATIONS
The following table sets forth, for income before extraordinary loss and for the
periods indicated, certain items from the Company's Consolidated Statements of
Income expressed as a percentage of net sales:
<TABLE>
<CAPTION>
FOR THE THREE MONTHS FOR THE SIX MONTHS
ENDED MAY 31, ENDED MAY 31,
-------------------- ---------------------
1999 1998 1999 1998
------ ------ ------ ------
<S> <C> <C> <C> <C>
NET SALES....................................... 100.0% 100.0% 100.0% 100.0%
----- ----- ----- -----
COSTS AND EXPENSES:
Cost of sales................................. 26.1 27.1 26.5 27.3
Advertising and promotion..................... 39.9 39.6 39.7 41.1
Selling, general and administrative........... 9.6 11.5 10.0 12.7
----- ----- ----- -----
Total costs and expenses.................... 75.6 78.2 76.2 81.1
----- ----- ----- -----
INCOME FROM OPERATIONS ......................... 24.4 21.8 23.8 18.9
----- ----- ----- -----
OTHER INCOME (EXPENSE):
Interest expense.............................. (11.2) (12.5) (12.4) (12.3)
Investment and other income................... .1 .4 .1 .4
Gain on product divestiture................... -- 17.8 -- 11.2
----- ----- ----- -----
Total other income (expense)............... (11.1) 5.7 (12.3) (.7)
----- ----- ----- -----
INCOME BEFORE INCOME TAXES ..................... 13.3 27.5 11.5 18.2
PROVISION FOR INCOME TAXES ..................... 5.0 10.3 4.3 6.8
----- ----- ----- -----
NET INCOME BEFORE EXTRAORDINARY
LOSS.......................................... 8.3% 17.2% 7.2% 11.4%
----- ----- ----- -----
----- ----- ----- -----
</TABLE>
13
<PAGE>
COMPARISON OF THREE MONTHS ENDED MAY 31, 1999 AND 1998
Net sales for the three months ended May 31, 1999 increased $24,896, or 42.5%,
to $83,441 from $58,545 for the same period last year. Domestic consumer
products sales increased $23,850, or 44.2%, to $77,795 from $53,945 for last
year's comparable period. Net sales of international consumer products increased
$1,046, or 22.7%, from $4,600 in the 1998 period to $5,646 in the current
period.
The increase in domestic consumer products sales in the 1999 period was
primarily due to the BAN and Thompson Medical brands acquired in March and
December 1998, respectively, and the continuing strong performance of the GOLD
BOND product line, especially GOLD BOND Medicated Body Lotion. Sales increases
were also registered for the PAMPRIN, SUN-IN, HERPECIN-L and PHISODERM product
lines, while decreases were experienced by the SUNSOURCE and BULLFROG brands.
With the exception of the CORNSILK brand, which was sold in May 1998, sales in
the current period of the remaining product lines were essentially flat or
showed modest declines as compared to the corresponding period of 1998. All
sales variances were largely the result of changes in the volume of unit sales
of the particular brands.
The increase in sales of the GOLD BOND product line was led by the introductions
of the Medicated Body Lotion product in the third quarter of fiscal 1998 and the
Triple Antibiotic Ointment in the first quarter of fiscal 1999, although sales
increases were also realized for the medicated powders and cream products. GOLD
BOND sales in the current period were also favorably affected by increased
marketing support. PHISODERM sales increases in the current period were largely
the result of the introduction of the 4 Way Daily Acne Cleanser line extension
and increased advertising and promotional expenditures. Sales increases for the
PAMPRIN and SUN-IN brands were largely the result of increased marketing
support, while the increase in sales of HERPECIN-L was primarily due to more
effective advertising. Also, SUN-IN sales in the 1999 period benefited from the
introduction of its Super Streaks product in February of the current year.
The sales decline in the current period for the SUNSOURCE products reflected the
general softening of sales in the dietary supplements' market. The decline in
BULLFROG sales in the current period was largely the result of reduced sales to
two larger customers.
International consumer products sales for the second quarter of fiscal 1999
increased $689, or 55.6%, for the Canadian operation but declined $347, or
11.8%, for the United Kingdom business. The increase in Canadian sales was
primarily associated with the BAN and certain of the Thompson Medical brands,
although sales increases were recorded for all of the remaining brands currently
being sold in Canada. Sales declines were recorded for all of the United Kingdom
brands, except for SUN-IN, largely due to generally weak economic conditions
presently existing in the United Kingdom and Western Europe. U.S. export sales
increased $704, or 165.8%, for the 1999 period as compared to the same period in
fiscal 1998, with practically all of the increase being associated with the BAN
product line. All sales variances were largely the result of changes in the
volume of unit sales of the particular brands.
Cost of goods sold as a percentage of net sales improved to 26.1% from 27.1% in
the 1998 period. The improvement was primarily the result of increased sales of
higher gross margin product lines in the current period.
14
<PAGE>
Advertising and promotion expenses increased $10,113, or 43.6%, and were
39.9% of net sales compared to 39.6% in the corresponding 1998 period. The
majority of the increase in the 1999 period was related to the BAN and
Thompson Medical brands, acquired in March and December 1998, respectively,
and to the GOLD BOND, FLEXALL, SUN-IN and PHISODERM product lines. Declines
were recorded for the HERPECIN-L, SUNSOURCE and CORNSILK brands. The CORNSILK
product line was sold in May 1998.
The increase of $1,243, or 18.4%, in selling, general and administrative
expenses in the 1999 period was largely associated with direct selling expenses,
resulting from increased sales, with research and development costs and with
various expenses of the general service departments of the Company. The selling,
general and administrative expenses were 9.6% of net sales in the current period
as compared to 11.5% in the same period of last fiscal year, reflecting the
increase in sales from newly acquired brands without a corresponding increase in
overhead costs.
Interest expense increased $2,010, or 27.4%, in the 1999 period, reflecting
primarily the additional debt incurred for the BAN and Thompson Medical brands'
acquisitions in March and December 1998, respectively.
An extraordinary loss of $1,873, net of taxes, related to the early
extinguishment of debt was recorded in 1999 period. The loss primarily related
to the write-off of debt issuance costs connected with outstanding long-term
debt retired before maturity in the current period, the premium paid on the
retirement of the 12.75% notes and termination of interest rate swaps.
Net income of $6,940 before extraordinary loss in the 1999 period was $3,345, or
93.0%, greater than the comparable 1998 amount of $3,595 after excluding the
gain of $6,474, net of taxes, on the sale of the CORNSILK brand. This increase
was largely the result of increased sales, offset in part by increased interest
expense, advertising and promotion expense and selling, general and
administrative costs.
15
<PAGE>
COMPARISON OF SIX MONTHS ENDED MAY 31, 1999 AND 1998
Net sales for the six months ended May 31, 1999 increased $52,703, or 56.4%, to
$146,169 from $93,466 for the same period last year. Domestic consumer products
sales increased $51,576, or 60.1%, to $137,338 from $85,762 for last year's
comparable period. Net sales of international consumer products increased
$1,127, or 14.6%, from $7,704 in the 1998 period to $8,831 in the current
period.
The increase in domestic consumer products sales in the 1999 period was
primarily due to the BAN and Thompson Medical brands acquired in March and
December 1998, respectively, and the continuing strong performance of the GOLD
BOND family of products, especially GOLD BOND Medicated Body Lotion. Sales
increases were also registered for the PAMPRIN, SUN-IN, HERPECIN-L and PHISODERM
product lines, while decreases were experienced by the SUNSOURCE and BULLFROG
brands. With the exception of the CORNSILK brand, which was sold in May 1998,
sales in the current period of the remaining product lines were essentially flat
or showed modest declines as compared to the corresponding period of 1998. All
sales variances were largely the result of changes in the volume of unit sales
of the particular brands.
The increase in sales of the GOLD BOND product line was led by the introductions
of the Medicated Body Lotion product in the third quarter of fiscal 1998 and the
Triple Antibiotic Ointment in the first quarter of 1999, although sales
increases were also realized for the medicated powders and cream products. GOLD
BOND sales in the current period were also favorably affected by increased
marketing support. PHISODERM sales increases in the current period were largely
the result of the introduction of the 4 Way Daily Acne Cleanser line extension
and increased advertising and promotional expenditures. Sales increases for the
PAMPRIN and SUN-IN brands were largely the result of increased marketing
support, while the increase in sales of HERPECIN-L was primarily due to more
effective advertising. Also, SUN-IN sales in the 1999 period benefited from the
introduction of its Super Streaks product in February of the current year.
The sales decline in the current period for the SUNSOURCE products reflected the
general softening of sales in the dietary supplements' market. The decline in
BULLFROG sales in the current period was largely the result of reduced sales to
two larger customers.
International consumer products sales for the first half of fiscal 1999
increased $924, or 42.9%, for the Canadian operation but declined $1,139, or
23.7%, for the United Kingdom business. The increase in Canadian sales was
primarily associated with the BAN and certain of the Thompson Medical brands,
although sales increases were recorded for all of the remaining brands currently
being sold in Canada. Sales declines were recorded for all of the United Kingdom
brands, except for SUN-IN, largely due to generally weak economic conditions
presently existing in the United Kingdom and Western Europe. U.S. export sales
increased $1,342, or 182.0%, for the 1999 period as compared to the same period
in fiscal 1998, with practically all of the increase being associated with the
BAN product line. All sales variances were largely the result of changes in the
volume of unit sales of the particular brands.
Cost of goods sold as a percentage of net sales improved to 26.5% from 27.3% in
the 1998 period. The improvement was primarily the result of increased sales of
higher gross margin product lines in the current period.
16
<PAGE>
Advertising and promotion expenses increased $19,671, or 51.3%, and were
39.7% of net sales compared to 41.1% in the corresponding 1998 period. The
majority of the dollar increase in the 1999 period was related to the BAN and
Thompson Medical brands acquired in March and December 1998, respectively,
and to the GOLD BOND, SUN-IN and PHISODERM product lines. Declines were
recorded for the HERPECIN-L, SUNSOURCE and CORNSILK brands. The CORNSILK
product line was sold in May 1998.
The increase of $2,784, or 23.4%, in selling, general and administrative
expenses in the 1999 period was largely associated with direct selling expenses,
resulting from increased sales, with research and development costs and with
various expenses of the general service departments of the Company. The selling,
general and administrative expenses were 10.0% of net sales in the current
period as compared to 12.7% in the same period of last fiscal year, reflecting
the increase in sales from newly acquired brands without any significant
corresponding increase in overhead costs.
Interest expense increased $6,636, or 57.6%, in the 1999 period, reflecting
primarily the additional debt incurred for the BAN and Thompson Medical brands'
acquisitions in March and December 1998, respectively.
An extraordinary loss of $2,300, net of taxes, related to the early
extinguishment of debt was recorded in 1999 period. The loss primarily related
to the write-off of debt issuance costs connected with outstanding long-term
debt retired before maturity in the current period, the premium paid on the
retirement of the 12.75% notes and termination of interest rate swaps.
Net income of $10,517 before extraordinary loss in the 1999 period was $6,313,
or 150.2% greater than the comparable 1998 amount of $4,204 after excluding the
gain of $6,474, net of taxes, on the sale of the CORNSILK brand. This increase
was largely the result of increased sales, offset in part by increased interest
expense, advertising and promotion expense and selling, general and
administrative costs.
LIQUIDITY AND CAPITAL RESOURCES
The Company has historically financed its operations with a combination of
internally generated funds and borrowings. The Company's principal uses of cash
are for operating expenses, long-term debt servicing, acquisitions, working
capital and capital expenditures.
Cash of $9,136 and $4,969 was provided by operations for the six months ended
May 31, 1999, and 1998, respectively. The increase in cash flows from operations
over the prior year period was primarily the result of increases in net income
(after adjusting for the gain on the sale of the CORNSILK product line in the
fiscal 1998 period) and depreciation and amortization.
Investing activities used cash of $94,526 and $161,019 in the six months ended
May 31, 1999 and 1998, respectively. The decrease of $66,493 in the current
period primarily represented the difference in the size of the acquisitions of
BAN in March 1998 and the Thompson Medical brands in December 1998.
Financing activities provided cash of $88,196 in the six months ended May 31,
1999 compared to $159,663 for the comparable prior year period. The decrease of
$71,467 in the current period reflected principally the difference in the
financing required for the BAN acquisition in March 1998 and for the Thompson
Medical brands in December 1998.
17
<PAGE>
The following table presents working capital data at May 31, 1999 and November
30, 1998 or for the respective periods then ended:
<TABLE>
<CAPTION>
May 31, November 30,
ITEM 1999 1998
------------ ------------ ------------
<S> <C> <C>
Working capital (current assets less current liabilities) ....... $ 25,838 $ 684
Current ratio (current assets divided by current liabilities) ... 1.40 1.01
Quick ratio (cash and cash equivalents and accounts
receivable divided by current liabilities)..................... .98 .63
Average accounts receivable turnover............................. 5.29 6.81
Average inventory turnover....................................... 3.40 3.57
Working capital as a percentage of total assets ................. 5.28% .19%
</TABLE>
The improvement in the current and quick ratios at May 31, 1999 as compared to
November 30, 1998, reflected primarily increases in accounts receivable and
inventories, which were largely associated with the Thompson Medical brands
acquired in December 1998, the seasonal products, e.g., BULLFROG and SUN-IN, and
the reduction of the current maturities of long-term debt.
Total loans outstanding were $387,547 at May 31, 1999 compared to $291,357 at
November 30, 1998, an increase of $96,190 during the first half of fiscal 1999.
This increase was primarily the result of additional loans required to purchase
the Thompson Medical brands in December 1998. The principal balances outstanding
at May 31, 1999 of the term loan, the revolving credit facility and total senior
subordinated notes were $70,000, $0 and $317,901, respectively.
Management of the Company believes that projected cash flows generated by
operations along with funds available under its credit facilities will be
sufficient to fund the Company's current commitments and proposed operations.
Also, on December 21, 1998, the Company filed a shelf registration statement
with the Securities and Exchange Commission for $250,000 of debt and equity
securities of which $75,000 of notes were issued during the first half of fiscal
1999.
18
<PAGE>
YEAR 2000
The Company recognizes the need to ensure its operations will not be adversely
impacted by year 2000 software failures. Software failures due to processing
errors potentially arising from calculations using the year 2000 date are a
known risk. The Company has developed a plan to ensure its systems are compliant
with the requirements to fulfilling those compliance requirements:
THE COMPANY'S STATE OF READINESS
The Company is in the process of replacing its current information technology
("IT") systems with a new fully integrated computer system to replace all
hardware and software that the Company uses in its financial, manufacturing and
customer services functions. The new IT system will be year 2000 compliant.
Accordingly, the year 2000 compliance requirements are considered only a portion
of the Company's system replacement effort. This replacement is expected to be
completed on or before December 1, 1999, the beginning of the Company's 2000
fiscal year. Although the Company believes that the new IT system will be year
2000 compliant, the Company uses third party equipment and software that may not
be year 2000 compliant. If any of this software or equipment does not operate
properly in the year 2000 and thereafter, the Company could be forced to make
unanticipated expenditures to cure these problems, which could adversely affect
the Company's business.
COST TO ADDRESS YEAR 2000 ISSUES
The total cost of the new software and implementation necessary to replace the
Company's current IT system plus address the year 2000 issues is estimated to be
approximately $2,000. Plan costs have been budgeted in the Company's capital
expenditures budget. The projected costs are based on management's best estimate
and actual results could differ as the new system is implemented. Approximately
$1,774 had been expended and capitalized on this system at May 31, 1999.
RISK OF YEAR 2000 ISSUES
The Company is in the process of execution of its formal year 2000 compliance
plan and expects to achieve implementation on or before December 1, 1999.
The Company is requesting from certain of its principal customers and suppliers
written statements regarding their knowledge of and plans for meeting the year
2000 compliance requirements. All respondents indicate that they have knowledge
of and are in the process of fulfilling these requirements. These companies have
stated that they are at various stages of completion of their compliance plans,
but all have indicated that they expect to be in full year 2000 compliance by or
before the end of their 1999 fiscal year.
In the event that the Company or any of its significant customers or suppliers
does not successfully and timely achieve year 2000 compliance, the Company's
business or operations could be adversely affected.
19
<PAGE>
CONTINGENCY PLANS
The Company is currently developing a "Worst Case Contingency Plan", which will
include generally an environment of utilizing "Work Force", "Spreadsheet" and
"Work Around" programming and procedural efforts. This contingency system will
be activated by December 1, 1999, if necessary. The cost of these temporary
measures is estimated between $500 and $1,000.
The Company's current existing systems are fully capable (except for year 2000
date handling) of processing all present and future transactions of the
business. Accordingly, no major efforts have been delayed or avoided which
affect normal business operations as a result of the incomplete implementation
of the year 2000 IT systems. These current systems will become the foundation of
the Company's contingency system.
FOREIGN OPERATIONS
The Company's primary foreign operations are conducted through its Canadian and
U.K. subsidiaries. The functional currencies of these subsidiaries are Canadian
dollars and British pounds, respectively. Fluctuations in exchange rates can
impact operating results, including total revenues and expenses, when
translations of the subsidiary financial statements are made in accordance with
SFAS No. 52, "Foreign Currency Translation." For the six months ended May 31,
1999 and 1998, these subsidiaries accounted for 5% and 7% of total revenues,
respectively, and 2% of total assets for each period, respectively. It has not
been the Company's practice to hedge its assets and liabilities in Canada and
the U.K. or its intercompany transactions due to the inherent risks associated
with foreign currency hedging transactions and the timing of payments between
the Company and its two foreign subsidiaries. Historically, gains or losses from
foreign currency transactions have not had a material impact on the Company's
operating results. Losses of $1 and $45 for the six months ended May 31, 1999
and 1998, respectively, resulted from foreign currency transactions.
20
<PAGE>
FORWARD LOOKING STATEMENTS
The Company may from time to time make written and oral forward looking
statements. Written forward looking statements may appear in documents filed
with the Securities and Exchange Commission, in press releases and in reports to
shareholders. The Private Securities Litigation Reform Act of 1995 contains a
safe harbor for forward looking statements. The Company relies on this safe
harbor in making such disclosures. The forward looking statements are based on
management's current beliefs and assumptions about expectations, estimates,
strategies and projections for the Company. These statements are not guarantees
of future performance and involve risks, uncertainties and assumptions that are
difficult to predict. Therefore, actual outcomes and results may differ
materially from what is expressed or forecasted in such forward looking
statements. The Company undertakes no obligation to update publicly any forward
looking statements whether as a result of new information, future events or
otherwise. The risks, uncertainties and assumptions regarding forward looking
statements include, but are not limited to, product demand and market acceptance
risks; product development risks, such as delays or difficulties in developing,
producing and marketing new products or line extensions; the impact of
competitive products, pricing and advertising; constraints resulting from
financial condition of the Company, including the degree to which the Company is
leveraged, debt service requirements and restrictions under bank loan agreements
and indentures; government regulations; risks of loss of material customers;
public perception regarding the Company's products; dependence on third party
manufacturers; environmental matters; product liability and insurance; year
2000; and other risks described in the Company's Securities and Exchange
Commission filings.
21
<PAGE>
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
In February 1999 a complaint was filed against the Company by Genderm
Corporation ("Genderm") in the U.S. District Court for the District of Arizona.
The complaint alleged, among other things, that the formulations of CAPZASIN-P,
CAPZASIN-HP and ICY HOT Arthritis Therapy Gel infringed U.S. Patent 4,485,450
owned by Joel Bernstein, M.D. and licensed to Genderm (the "Patent"). The
complaint requested injunctive relief, compensatory and treble damages, costs
and attorneys fees. A hearing on the preliminary injunction was held on April 13
- - 14, 1999. On May 6, 1999 U.S. District Court for the District of Arizona
held that Genderm had carried its burden of proving a substantial likelihood of
success and ultimately showing that the Patent was infringed and issued a
preliminary injunction prohibiting the Company from shipping CAPZASIN-P cream,
CAPZASIN-HP cream and ICY HOT Arthritis Therapy Gel. Following the issuance of
the preliminary injunction, Chattem reached a settlement with Genderm pursuant
to which Chattem made a single payment in exchange for the dismissal of the
complaint and a fully paid license to use the Patent until its expiration.
ITEM 4. SUBMISSIONS OF MATTERS TO A VOTE OF SECURITY HOLDERS
The annual meeting of shareholders was held on April 14, 1999 in
Chattanooga Tennessee. At the meeting, the following persons were elected as
directors to serve for a three year term: Samuel E. Allen, Philip H. Sanford and
A. Alexander Taylor II. With respect to Mr. Allen, 7,726,016 were in favor and
742,998 abstain. With respect to Mr. Sanford, 7,725,460 were in favor and
743,553 abstain. With respect to Mr. Taylor, 7,725,685 were in favor and 743,328
abstain. The following directors' terms of office continued after the annual
meeting: Zan Guerry, Louis H. Barnett, Robert E. Bosworth, Richard E. Cheney and
Scott L. Probasco, Jr.
The proposal to increase the number of authorized shares of the
Company's common stock, without par value, to 50,000,000 from 20,000,000 shares
was approved with 7,027,433 votes in favor, 1,436,096 opposed and 5,484
abstaining.
The 1999 Chattem, Inc. Stock Plan for Non-Employee Directors was
approved by the shareholders with 8,105,915 votes in favor, 301,086 opposed,
26,159 abstaining and 35,853 broker non-votes.
The shareholders approved Arthur Andersen LLP as auditors for the next
fiscal year with 8,451,149 votes in favor, 4,095 opposed and 3,769 abstaining.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits:
(1) Statement regarding computation of per share earnings
(Exhibit 11).
(2) Financial data schedule (Exhibit 27).
(b) No Form 8-K reports were filed with the Securities and Exchange
Commission during the three months ended May 31, 1999.
22
<PAGE>
CHATTEM, INC.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CHATTEM, INC.
(Registrant)
Dated: JULY 14, 1999 \s\ A. ALEXANDER TAYLOR II
---------------------- ---------------------------
A. Alexander Taylor II
President and Director
(Chief Operating Officer)
\s\ STEPHEN M. POWELL
---------------------------
Stephen M. Powell
(Chief Accounting Officer)
23
<PAGE>
EXHIBIT 11
CHATTEM, INC. AND SUBSIDIARIES
STATEMENT REGARDING COMPUTATION OF PER SHARE EARNINGS
(UNAUDITED AND IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
<TABLE>
<CAPTION>
FOR THE THREE MONTHS FOR THE SIX MONTHS
ENDED MAY 31, ENDED MAY 31,
------------------------- --------------------------
1999 1998 1999 1998
------------ --------- ---------- -----------
<S> <C> <C> <C> <C>
NET INCOME:
Income before extraordinary loss..... $ 6,940 $ 10,069 $ 10,517 $ 10,678
Extraordinary loss................... (1,873) (1,901) (2,300) (1,901)
---------- --------- --------- ----------
Net income......................... $ 5,067 $ 8,168 $ 8,217 $ 8,777
---------- --------- --------- ----------
---------- --------- --------- ----------
COMMON SHARES:
Weighted average number outstanding.. 9,741 9,370 9,726 9,149
Number issued upon assumed exercise
of outstanding stock options and
stock warrants..................... 371 459 379 399
---------- --------- --------- ----------
Weighted average and dilutive potential
number outstanding................. 10,112 9,829 10,105 9,548
---------- --------- --------- ----------
---------- --------- --------- ----------
NET INCOME (LOSS) PER COMMON SHARE:
Basic:
Income before extraordinary loss.. $ .71 $ 1.07 $ 1.08 $ 1.17
Extraordinary loss................ (.19) (.20) (.24) (.21)
---------- --------- --------- ----------
Total basic................... $ .52 $ .87 $ .84 $ .96
---------- --------- --------- ----------
---------- --------- --------- ----------
Diluted:
Income before extraordinary loss.. $ .69 $ 1.02 $ 1.04 $ 1.12
Extraordinary loss................ (.19) (.19) (.23) (.20)
---------- --------- --------- ----------
Total diluted................. $ .50 $ .83 $ .81 $ .92
---------- --------- --------- ----------
---------- --------- --------- ----------
</TABLE>
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM CHATTEM,
INC.'S UNAUDITED FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> NOV-30-1999
<PERIOD-START> DEC-01-1998
<PERIOD-END> MAY-31-1999
<CASH> 4,869
<SECURITIES> 0
<RECEIVABLES> 59,250
<ALLOWANCES> 850
<INVENTORY> 22,980
<CURRENT-ASSETS> 90,456
<PP&E> 39,126
<DEPRECIATION> 18,870
<TOTAL-ASSETS> 489,776
<CURRENT-LIABILITIES> 64,618
<BONDS> 378,547
0
0
<COMMON> 2,034
<OTHER-SE> 35,601
<TOTAL-LIABILITY-AND-EQUITY> 489,776
<SALES> 146,169
<TOTAL-REVENUES> 146,169
<CGS> 38,674
<TOTAL-COSTS> 111,411
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 18,148
<INCOME-PRETAX> 16,854
<INCOME-TAX> 6,337
<INCOME-CONTINUING> 10,517
<DISCONTINUED> 0
<EXTRAORDINARY> (2,300)
<CHANGES> 0
<NET-INCOME> 8,217
<EPS-BASIC> .84
<EPS-DILUTED> .81
</TABLE>
